Forms of iron binding in the cells and the chemical features of chelation therapy

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 9, 2009, Pages 1136-1146

  Puntarulo, S ^a   Galleano, M ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; EDETIC ACID; IRON; IRON CHELATING AGENT; N,N DIMETHYL 2,3 DIHYDROXYBENZAMIDE; PENTETIC ACID; UNCLASSIFIED DRUG;

CELL TRANSPORT; CHELATION THERAPY; CHEMICAL ANALYSIS; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG BINDING; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; HEMOCHROMATOSIS; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; NONHUMAN; OXIDATION; PHYSICAL CHEMISTRY; REVIEW; THALASSEMIA; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; CHELATION THERAPY; HUMANS; IRON; IRON CHELATING AGENTS;

EID: 70349573753     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788922674     Document Type: Review

References (86)

1. Harrison, P.M.; Arosio, P. The ferritins: molecular properties, iron storage functions and cellular regulation. Biochim. Biophys. Acta, 1996, 1275, 161-203. (Pubitemid 26248989)
2. Crichton, R.R.; Ward, R.J. Iron metabolism-New perspectives in view. Biochemistry, 1992, 31, 11255-11264
3. Pierre, J.L.; Fontecave, M.; Crichton, R.R. Chemistry for essential biological process: the reduction of ferric iron. BioMetals, 2002, 15, 341-346
4. Guerinot, M.L.; Yi, Y. Iron: nutritious, noxious, and not readily available. Plant Physiol., 1994, 104, 815-820 (Pubitemid 24987458)
5. Galatro, A.; Puntarulo, S. Mitochondrial ferritin in animals and plants. Front. Biosci., 2007, 12, 1063-1071
6. Beard, J.L.; Dawson, B.S.; Piñero, D.J. Iron metabolism: a comprehensive review. Nut. Rev., 1996, 54, 295-317.
7. Kruszewski, M. The role of labile iron pool in cardiovascular diseases. Acta Biochim. Pol., 2004, 51, 471-480 (Pubitemid 38969308)
8. Puntarulo S. Iron, oxidative stress and human health. Mol. Aspects Med., 2005, 26, 299-312. (Pubitemid 41225354)
9. Puntarulo, S.; Cederbaum, A.I. Stimulation of microsomal chemiluminescence by ferritin. Biochim. Biophys. Acta, 1993, 1157, 1-8.
10. Puntarulo, S.; Cederbaum, A.I. Ferritin-dependent inactivation of microsomal glucose-6-phosphatase. Biochim. Biophys. Acta, 1994, 1200, 41-47
11. Puntarulo, S.; Cederbaum, A.I. Inhibition of ferritin-stimulated microsomal production of reactive oxygen intermediates by nitric oxide. Arch. Biochem. Biophys, 1997, 340, 19-26. (Pubitemid 27200269)
12. Kozlov, A.V.; Bini, A.; Gallesi., D.; Biovannini, F.; Iannone, A.; Masini, A.; Meletti, E.; Tomasi, A. "Free" iron, as detected by electron paramagnetic resonance spectroscopy, increases unequally in different tissues during dietary iron overload in the rat. BioMetals, 1996, 9, 98-103. (Pubitemid 26041412)
13. Woodmansee, A.N.; Imlay, J.A. Quantitation of intracellular free iron by electron paramagnetic resonance spectroscopy. Meth. Enzymol., 2002, 349, 3-9. (Pubitemid 34229488)
14. Kakhlon, O.; Cabantchik, Z.I. The labile iron pool: characterization, measurement, and participation in cellular processes (1). Free Radic. Biol. Med., 2002, 33, 1037-1046
15. Petrat, F.; de Groot, H.; Sustmann, R.; Rauen, U. The chelatable iron pool in living cells: a methodically defined quantity. Biol. Chem., 2002, 383, 489-502. (Pubitemid 34506286)
16. Kruszewski, M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat. Res., 2003, 531, 81-92. (Pubitemid 37456724)
17. Puntarulo, S.; Cederbaum, A.I. Comparison of the ability of the ferric complexes to catalyze microsomal chemiluminescence, lipid peroxidation and hydroxyl radical generation. Arch. Biochem. Biophys., 1988, 24, 482-491
18. Knutson, M.; Wessling-Resnick, M. Iron metabolism in the reticuloendothelial system. Crit. Rev. Biochem. Mol. Biol., 2003, 38, 61-88.
19. Le Lan, C.; Loréal, O.; Cohen, T.; Ropert, M.; Glickstein, H.; Lainé, F.; Pouchard, M.; Deugnier, Y.; Le Treut, A.; Breuer, W.; Cabantchik, Z.I.; Brissot, P. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood, 2005, 105, 4527-4531 (Pubitemid 40720804)
20. Gunshin, H.; Mackenzie, B.; Berger, U.V.; Gunshin, Y.; Romero, M.F.; Boron, W.F.; Nussberger, S.; Gollan, J.L.; Hediger, M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature, 1997, 388, 482-488
21. Chua, A.C.G.; Olynyk J.K.; Leedman P.J.; Trinder, D. Nontransferrin- bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis. Blood, 2004, 104, 1519-1525 (Pubitemid 39166533)
22. Cighetti, G.; Duca, L.; Bortone, L.; Sala, S.; Nava, I.; Fiorelli, G.; Capellini, M.D. Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur. J. Clin. Invest., 2002, 32, 55-60.
23. Gutteridge, J.M.; Rowley, D.A.; Griffiths, E.; Halliwell, B. Low-molecular- weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin. Sci. (Lond.), 1985, 68, 463-467 (Pubitemid 15127670)
24. Hider, R.C. Nature of nontransferrin-bound iron. Eur. J. Clin. Invest., 2002, 32, 50-54
25. Espósito, B.P.; Epsztejn, S.; Breuer, W.; Cabantchik, Z.I. A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal. Biochem., 2002, 304, 1-18. (Pubitemid 34492837)
26. Kozlov, A.V.; Yegorov, D.Y.; Vladimirov, Y.A.; Azizova, O.A. Intracellular free iron in liver tissue and liver homogenate: studies with electron paramagnetic resonance on the formation of paramagnetic complexes with desferal and nitric oxide. Free Radic. Biol. Med., 1992, 13, 9-16.
27. Cardoso, N.; Galleano, M. Metals and Oxidative Stress. Antioxidants On Line J., 2005, http://antioxidants.com.ar/Home102.htm.
28. Petrak, J.V.; Vyoral, D. Detection of iron-containing proteins contributing to the cellular labile iron pool by a native electrophoresis metal blotting technique. J. Inorg. Biochem., 2001, 86, 669-675 (Pubitemid 32907292)
29. Petrat, F.; de Groot, H.; Rauen, U. Subcellular distribution of chelatable iron: a laser scanning microscopic study in isolated hepatocytes and liver endothelial cells. Biochem. J., 2001, 356, 61-69 (Pubitemid 34275706)
30. Uchiyama, A.; Kim, J.S.; Kon, K.; Jaeschke, H.; Ikejima, K.; Watanabe, S.; Lemasters, J.J. Translocation of iron from lysosomes into mitochondria is a key event during oxidative stress-induced hepatocellular injury. Hepatology, 2008, 48; 1644-1654
31. Galatro, A.; Rousseau, I.; Puntarulo S. Ferritin role in iron toxicity in animals and plants. Curr. Top. Toxicol., 2007, 4, 65-76.
32. Chasteen, N.D.; Harrison, P.M. Mineralization in ferritin: An efficient means of iron storage. J. Struct. Biol., 1999, 126, 182-194
33. Limdi, J.K.; Crampton, J.R. Hereditary haemochromatosis. Q.J. Med., 2004, 97, 315-324
34. Andersen, R.V.; Tybjaerg-Hansen, A.; Appleyard, M.; Birgens, H.; Nordestgaard, B.G. Hemochromatosis mutations in the general population: iron overload progression rate. Blood, 2004, 103, 2914-2919 (Pubitemid 38451659)
35. Goyer, R.A.; Cherian, M.G.; Jones, M.M.; Reigart, J.R. Role of chelating agents for prevention, intervention, and treatment of exposures to toxic metals. Environ. Health. Perspect., 1995, 103, 1048-1052
36. Fontecave, M.; Pierre, J.L. Iron: metabolism, toxicity and therapy. Biochimie, 1993, 75, 767-773
37. Pootrakul, P.; Breuer, W.; Samtband, M.; Sirankapracha, P.; Hershko, C.; Cabantchik, Z.I. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded betathalassemia/ HbE patients treated with an oral chelator. Blood, 2004, 104, 1504-1510
38. Theil, E.C. Ferritin: at the crossroads of iron and oxygen metabolism. J. Nutr. 2003, 133, 1549S-53S.
39. Erdemoglu, A.K.; Ozbakir, S. Serum ferritin levels and early prognosis of stroke. Eur. J. Neurol., 2002, 9, 633-637 (Pubitemid 36961290)
40. Zhang, Q.; Huang, X. Induction of ferritin and lipid peroxidation by coal samples with different prevalence of coal workers' pneumoconiosis: role of iron in the coals. Am. J. Ind. Med., 2002, 42, 171-179 (Pubitemid 34907361)
41. Gulcelik, N.E.; Kayatas, M. Importance of serum ferritin levels in patients with renal failure. Nephron, 2002, 92, 230-231 (Pubitemid 34983902)
42. Sakata, S.; Nagai, K.; Maekawa, H.; Kimata, Y.; Komaki, T.; Nakamura, S.; Miura, K. Serum ferritin concentration in subacute thyroiditis. Metabolism, 1991, 40, 683-688
43. Berberat, P.O.; Katori, M.; Kaczamarek, E.; Anselmo, D.; Lassman, C.; KeShen, X.; Busuttil, R.W.; Yamashita, K.; Csizmandia, E.; Tyagi, S.; Otterbei-Brouard, S.; Tobiasch E.; Bach, F.H.; Kupiec-Weglinski, W.; Soares, M.P. Heavy chain ferritin acts as an antiapoptotic gene that protects livers from ischemia reperfusion injury. FASEB J., 2003, 17, 1724-1726
44. Armaganijan, D.; Batlouni, M. Serum ferritin levels and other indicators of organic iron as risk factors or markers in coronary artery disease. Rev. Port. Cardiol., 2003, 22, 185-195 (Pubitemid 36541492)
45. Dexter, D.T.; Wells, F.R.; Agid, F.; Agid, Y.; Lees, A.J.; Jenner, P.; Marsden, D. Increased nigral iron content in postmortem parkinsonian brain. Lancet, 1987, 8569, 1219-1220
46. Ponka, P. Hereditary causes of disturbed iron homeostasis in the central nervous system. Ann. N.Y. Acad. Sci, 2004, 1012, 267-281 (Pubitemid 38453531)
47. Chaston, T.B.; Richardson, D.R. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am. J. Hematol., 2003, 73, 200-210
48. Hershko, C.; Weatherall, D.J. Iron-chelating therapy. Crit. Rev. Clin. Lab. Sci., 1988, 26, 303-345
49. Liu, Z.D.; Hider, R.C. Design of iron chelators with therapeutic application. Coord. Chem. Rev., 2002, 232, 151-171
50. Crisponi, G.; Remelli, M. Iron chelating agents for the treatment of iron overload. Coord. Chem. Rev., 2008, 252, 1225-1240
51. Nick, H. Iron chelation, quo vadis?. Curr. Opin. Chem. Biol., 2007, 11, 419-423
52. Franchini, M; Gandini, G.; Aprili, G. Advances in iron chelating therapy. Haematologica, 2000, 85, 1122-1125
53. Pippard, M.J.; Callender, S.T.; Weatherall, D.J Intensive ironchelation therapy with desferrioxamine in iron-loading anaemias. Clin. Sci. Mol. Med., 1978, 54, 99-106.
54. Franchini, M; Gandini, G.; de Gironcoli, M.; Vassanelli, A.; Borgna- Pignatti, C.; Aprili, G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adults patients with iron overload. Blood, 2000, 95, 2776-2779
55. Olivieri, N. F.; Brittenham, G.M. Iron-chelation therapy and the treatment of thalasemia. Blood, 1991, 89, 739-761
56. Lowther, N.; Sparks, K.; Nicklin, J.; Jin, Y. A novel depot preparation of desferrioxamine-B: development of formulation principles. Drug Dev. Ind. Pharm., 1999, 25, 1157-1166
57. Galanello, R. Deferiprone in the treatment of transfusion-dependent talasemia: a review and perspective. Ther. Clin. Risk Manag., 2007, 3, 795-805. (Pubitemid 350162079)
58. Walter, P.B.; Macklin, E.A.; Porter, J.; Evans, P.; Kwiatkowski, J.L.; Neufeld, E.J.; Coates, T.; Giardina, P.J.; Vichinsky, E.; Olivieri, N.; Alberti, D.; Holland, J.; Harmatz, P. Inflammation and oxidative-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: and ancillay study of the Novartis CICL670A0107 trial. Haematologica, 2008, 93, 817-825
59. Pippard, M.J.; Jackson, M.J.; Hoffman, K.; Petrou, M.; Modell, C.B. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scand. J. Haematol.; 1986, 36, 466-472
60. Buettner, G.R. The pecking order of free radicals and antioxidants: lipid peroxidation, α-tocopherol, and ascorbate. Arch. Biochem. Biophys., 1993, 300, 535-543 (Pubitemid 23232908)
61. Tilbrook, G.S.; Hider, R.C. In Metal ions in biological systems: iron transport and storage in microorganisms, plants and animals; Sigel, A.; Sigel, H. Eds.; Marcel Dekker: New York, 1998; Vol 35, pp. 691.
62. Singh, S.; Khodr, H.; Taylor, M.I.; Hider, R.C. Therapeutic iron chelators and their potential side-effects. Biochem. Soc. Symp., 1995, 61, 127-137
63. Lipinski, C.A; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 3, 3-25.
64. Hider, R.C. Potential protection from toxicity by oral iron chelators. Toxicol. Lett., 1995, 82/83, 961-967
65. Liu, X.; Jin, W.; Theil, E.C. Opening protein pores with chaotropes enhances Fe reduction and chelation of Fe from the ferritin biomineral. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 3653-3658
66. Weinberg, E.D. Cellular iron metabolism in health and disease. Drug Metab. Rev., 1990, 22, 531-579
67. Metwally, M.A.; Zein, C.O.; Zein, N.N. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am. J. Gastroenterol., 2004, 99, 286-291 (Pubitemid 38279871)
68. Weinberg, E.D. Roles of iron in neoplasia. Promotion, prevention and therapy. Biol. Trace Elem. Res., 1992, 34, 123-140
69. Weinberg, E.D. Association of iron with respiratory neoplasia. J. Trace Elem. Exp. Med., 1993, 6, 117-123
70. Gackowski, D.; Kruszewski, M.; Bartlomiejczyk, T.; Jawien, A.; Ciecierski, M.; Olinski, R. The level of 8-oxo-7,8-dihydro-2′- deoxyguanosine is positively correlated with the size of the labile iron pool in human lymphocytes. J. Biol. Inorg. Chem., 2002, 7, 548-550 (Pubitemid 36061705)
71. Gackowski, D.; Kruszweski, M.; Jawien, A.; Ciecierski, M.; Olisnki, R. Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radic. Biol. Med., 2001, 31, 542-547
72. Sikorska, K.; Stalke, P.; Lakomy, E.A.; Michalska, Z.; Witczak- Malinowska, K.; Stolarczyk, J. Disturbances of iron metabolism in chronic liver diseases. Med. Sci. Monit., 2003, 9, 64-67.
73. Galleano, M.; Lemberg, A.; Puntarulo, S. Does hepatomegaly alter iron-dependent oxidative effects in human plasma?. Hum. Exp. Toxicol., 2003, 22, 401-405 (Pubitemid 36987234)
74. McCarty, M.F. Hyperinsulinemia may boost both hematocrit and iron absorption by up-regulating activity of hypoxia-inducible factor- 1α. Med. Hypotheses, 2003, 61, 567-573
75. Piperno, A.; Trombini, P.; Gelosa, M.; Mauri, V.; Pecci, V.; Vergani, A.; Salvioni, A.; Mariani, R.; Macia, G. Increased serum ferritin is common in men with essential hypertension. J. Hypertens., 2002, 20, 1513-1518
76. Patrinos, G.P.; Kollia, P.; Papadakis, M.N. Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies. Hum. Mutat., 2005, 26, 399-412. (Pubitemid 41572447)
77. Curtis, A.R., Fey, C., Morris, C.M., Bindoff, L.A., Ince, P.G., Chinnery, P.F., Coulthard, A., Jackson, M.J., Jackson, A.P., McHale, D.P., Hay, D., Barker, W.A., Markham, A.F., Bates, D., Curtis, A.; Burn, J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet., 2001, 28, 350-354 (Pubitemid 32702424)
78. Becker, E.; Richardson, D.R. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int. J. Biochem. Cell Biol., 2001, 33, 1-10.
79. Hayflick, S.J. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated nerurodegeneration is the name. Curr. Opin. Pediatr., 2003, 1, 572-577 (Pubitemid 37487371)
80. Zhou, B., Westaway. S.K., Levinson, B., Johnson, M.A., Gitschier, J.; Hayflick, S.J. A novel panthothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat. Genet., 2001, 28, 345-349 (Pubitemid 32702423)
81. Yoon, S.J.; Koh, Y.Y.; Floyd, R.A.; Park, J.W. Cooper, zinc superoxide dismutase enhances DNA damage and mutagenicity induced by cysteine/iron. Mutat. Res., 2000, 448, 97-104.
82. Merkofer, M.; Kissner, R.; Hider, R.C.; Koppenol, W.H. Redox properties of the iron complexes of orally active iron chelators CP20, CP502, CP509, and ICL570. Helv. Chim. Acta, 2004, 87, 3021-3034
83. Cooper, S.R., McArdle, J.V.; Raymond, K.N. Siderophore electrochemistry: relation to intracellular iron release mechanism. Proc. Natl. Acad. Sci USA, 1978, 75 3551-3554
84. Nick, H.P.; Acklin, P.; Faller, B.; Jin, Y.; Lattmann, R.; Rouan, M.- C.; Sergejew, T.; Thomas, H.; Wiegand, H.; Schnebli, H.P. In Iron chelators, new development strategies; DG Badman, RJ Bergeron, GM Brittenham, Eds.;. The Saratoga Group: Florida, 2000, pp. 311.
85. Steinhauser, S.; Heinz, U.; Bartholomä, M.; Weyhermülller, T.; Nick, H.; Hegetschweiler, K. Complex formation of ICL670 and related ligands with FeIII and FeII. Eur. J. Inorg., 2004, 21, 4177-4192
86. El-Jammal, A.; Templeton, D. M. Iron-hydroxypyridone redox chemistry: kinetic and thermodynamic limitations to Fenton activity. Inorg. Chim. Acta, 1996, 245, 199-207.